替罗非班序贯联合双抗血小板治疗急性缺血性脑梗死的疗效观察

Observation on the curative effect of tirofiban sequential combined with dual antiplatelet in the treatment of acute ischemic cerebral infarction

目的探讨替罗非班序贯联合双抗血小板治疗急性缺血性脑梗死的临床疗效观察。方法将2021年6月~2022年6月我院收治的116例急性缺血性脑梗死患者,通过随机数字表法将入组患者分为2组,分别为实验组58例和对照组58例。对照组患者采用替格瑞洛90mg联合阿司匹林100mg治疗30d。实验组患者入院24h内先接受替罗非班静脉泵入,前30min速率为0.4μg·kg^(-1)·min^(-1),之后改为0.1μg·kg^(-1)·min^(-1),共持续48h。再用替格瑞洛90mg联合阿司匹林100mg双抗治疗,参考对照组的用法用量及治疗时间,持续治疗30d。比较两组治疗30d后美国国立卫生院卒中量表(NIHSS)、Rankin量表(mRS)评分、不良反应。结果治疗30d后,实验组患者的美国国立卫生院卒中量表(NIHSS)评分和Rankin量表评分明显低于对照组(P<0.05)。实验组的治疗总有效率较对照组更高(P<0.05)。2组不良反应发生率比较无统计学意义(P>0.05)。结论在急性缺血性脑梗死患者中给予替罗非班联合双抗血小板治疗效果显著,可以缓解神经功能损伤,且不良反应较小。

Objective To investigate the clinical efficacy of tirofiban sequential combined with dual antiplatelet in the treatment of acute ischemic cerebral infarction.Methods 116 patients with acute ischemic cerebral infarction admitted to our hospital from June 2021 to June 2022 were divided into experimental group(57 cases)and control group(59 cases)according to different medication schemes.The experimental group was treated with tirofiban,aspirin and tegrel for 19 days;The patients in the control group were treated with tegrel and aspirin for 30 days.The scores of the National Institutes of Health Stroke Scale(NIHSS),Rankin Scale(mRS)and adverse reactions were compared between the two groups after 30 days of treatment.Results After 30 days of treatment,the scores of NIHSS and Rankin scale in the experimental group were significantly lower than those in the control group(P<0.05).The total effective rate of treatment in the experimental group was higher than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion In patients with acute ischemic cerebral infarction,tirofiban combined with dual antiplatelet therapy has a significant effect,can alleviate the nerve function damage,and has less adverse reactions.